Company Profiles

driven by the PitchBook Platform

Xention

Description

Developer of ion channel-modulating drugs for therapeutic intervention. The company offers drugs for the treatment of atrial fibrillation, overactive bladder, pain and autoimmune diseases.

2002

Founded

PRIVATE

Status

11-50

Employees

Later Stage VC

Latest Deal Type

$3.07M

Latest Deal Amount

$48.1M

Total Amount Raised

Description

Developer of ion channel-modulating drugs for therapeutic intervention. The company offers drugs for the treatment of atrial fibrillation, overactive bladder, pain and autoimmune diseases.

Website:

www.xention.com

Formerly Known As

Xention Discovery

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Delivery

Other Industries

Drug Discovery

Primary Office

Unit 5, Quern House Mill Court, Hinton Way, Great Shelford Cambridge CB22 5LDEngland +44 (0)12 2349 3900
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Xention's full profile, request a free trial.

    Xention Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Xention Investors (13)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    ABN AMRO BankInvestment BankMinority000 0000000 0000
    Albany Venture ManagersVenture CapitalMinority000 0000000 0000
    Albion CapitalVenture CapitalMinority000 0000000 0000
    BTGCorporationMinority000 0000000 0000
    Enterprise VenturesVenture CapitalMinority000 0000000 0000
    ABN AMRO Bank Investment Bank
    Albany Venture Managers Venture Capital
    Albion Capital Venture Capital
    BTG Corporation
    Enterprise Ventures Venture Capital

    Xention Executive Team (5)

    NameTitleBoard
    Seat
    Contact
    Info
    Patrick RoundBoard Member, Chief Medical Officer & Chief Executive Officer
    Rebecca HemsleyDirector, Finance & Chief Financial Officer
    James Milnes Ph.DVP, Preclinical Development
    Keith MccullaghBoard Member & Executive Chairman
    John Ford Ph.DCo-Founder & Chief Scientific Officer
    Patrick Round Board Member, Chief Medical Officer & Chief Executive Officer
    Rebecca Hemsley Director, Finance & Chief Financial Officer
    James Milnes Ph.D VP, Preclinical Development
    Keith Mccullagh Board Member & Executive Chairman
    John Ford Ph.D Co-Founder & Chief Scientific Officer

    Xention Board Members (13)

    NameRepresentingRoleSinceContact
    Info
    Alan O'Connell Ph.DSeroba Life SciencesPartner000 0000
    Andrew ElderAlbion CapitalPartner000 0000
    Angel MitevSelfBoard Member000 0000
    Bruno Montanari Ph.DOmnes CapitalPartner000 0000
    Charles Gee Ph.DSPARKVenturesInvestment Director, Healthcare000 0000
    Alan O'Connell Ph.D Partner Seroba Life Sciences
    Andrew Elder Partner Albion Capital
    Angel Mitev Board Member Self
    Bruno Montanari Ph.D Partner Omnes Capital
    Charles Gee Ph.D Investment Director, Healthcare SPARKVentures
    Request full access to PitchBook